CD4 and neoplasm: While treatment with β-lap alone or β-lap combined with CD4+ T cell depletion controlled MC38 tumor growth, CD8+ T cells depletion abolished β-lap’s antitumor effect (Fig. 2b, Supplementary Fig. 2c), suggesting that CD8+ T cells, but not CD4+ T cells, are required for β-lap-mediated tumor regression.